Chairman of the Board, Chief Executive Officer & Managing Director
Mr. Jamison has served as Chairman and Chief Executive Officer since January 2009; as President and Chief Operating Officer from January 2005 to December 2008; as Treasurer from March 2005 to May 2008; as a Managing Director since January 2004; as Chief Financial Officer from January 2005 to December 2007; and as Vice President from September 2002 to December 2004. He has been a member of our Board of Directors since May 2007. Since January 2009, he has served as Chairman and Chief Executive Officer of Harris & Harris Enterprises, Inc., a wholly owned subsidiary of the Company, since 2005, he has served as a Director; and from January 2005 to December 2008 he served as President . From 1998 to 2002, Mr. Jamison worked as a Senior Technology Manager at the University of Utah Technology Transfer Office, where he managed intellectual property for the University of Utah. This included assessing technologies in both the biological sciences and the physical sciences, working with patent attorneys to develop patent protection, and developing and marketing these technologies with industry. He is a Co-Editor-in-Chief, Journal of Nanotechnology Law & Business and Co-Chair of the Advisory Board, Converging Technology Bar Association and a member of the University of Pennsylvania Nano-Bio Interface Ethics Advisory Board. He was graduated from Dartmouth College (B.A.) and the University of Utah (M.S.).
Portfolio responsibilities: Ancora Pharmaceuticals, Mersana Therapeutics, Metabolon, Nextreme Thermal Solutions and Solazyme.
Mr. Ayres is Chief Operating Officer of Cold Spring Harbor Laboratory, a research and educational institution in the biological sciences since November 2000. Prior to joining Cold Spring Harbor Laboratory in 1998, Mr. Ayres had a 20-year business career during which he worked as a corporate executive, investment banker and entrepreneur. In 1996, he co-founded Business & Trade Network, Inc., a business-to-business, venture capital-backed internet company. Prior to that he worked for five years as a Managing Director of Veronis, Suhler & Associates, a boutique investment banking firm in New York specializing in the media/communications industry. At Veronis, Suhler, he focused on investing the firms's private equity fund. He was graduated from Princeton University (A.B.) and from Columbia University Graduate Shcool of Business (M.B.A. in Finance)
Dr. Bardin is President of Bardin LLC, a consulting firm to pharmaceutical companies. He also serves on the Board of Health Advocates for Older People. From 1998 to 2003, he served as President of Thyreos Corp., a privately held, start-up pharmaceutical company. From 1978 through 1996, he was Vice President of The Population Council, an international non-profit organization focusing on population issues. He has held appointments as Professor of Medicine, Chief of the Division of Endocrinology, The Milton S. Hershey Medical Center of Pennsylvania State University, and Senior Investigator, Endocrinology Branch, National Cancer Institute. He has directed basic and clinical research leading to over 500 publications and patents. He has also served as a consultant to several pharmaceutical companies. He has been appointed to the editorial boards of 15 journals. He has served on committees and boards for the National Institute of Health, World Health Organization, The Ford Foundation, and various scientific societies. He was graduated from Rice University (B.A.), from Baylor University (M.S., M.D.) and he received a Doctor Honoris Causa from the University of Caen, the University of Paris, and the University of Helsinki.
Dr. Bauman is a practicing orthopedic surgeon. Since 1999, he has been Senior Attending in Orthopedic Surgery at St. Luke's/Roosevelt Hospital Center in Manhattan and since 2000 has served as an elected member of the Executive Committee of the Medical Board. Since 2005, he has been on the Board of Managers for the Hudson Crossing Surgery Center. Since 1997, he has been Assistant Professor of Orthopedic Surgery at Columbia University and since 1994, a Vice President of Orthopedic Associates of New York. In 1991, he was elected a fellow of the American Academy of Orthopaedic Surgeons. Since 2005, he has consulted for Skyline Venture Partners, a venture capital firm specializing in healthcare companies. He is an active member of the American Orthopaedic Society for Sports Medicine, the American Orthopaedic Foot and Ankle Society, the New York State Society of Orthopaedic Surgeons, the New York State Medical Society and the American Medical Association. He was graduated from Harvard College (A.B.), Harvard University (A.M., Biology) and the College of Physicians and Surgeons at Columbia University (M.D.).
Mr. Browne is President since 2004 and a Trustee since 2000 of Planting Fields Foundation, a supporting institution of Planting Fields Arboretum State Historic Park. Since 2004, he has been a Director and Treasurer of the Society for Preservation Long Island Antiquities. Since 1987, he has been a director of Huntington Hospital. From 2001 to 2003, he served as Chief Financial Officer of Cold Spring Harbor Laboratory, a not-for-profit institution that conducts research and education programs in the biological sciences; he was its Administrative Director from 1985 to 2000. In prior years, he was active in the management of numerous scientifically based companies as an officer, as an individual consultant and as an associate of Laurent Oppenheim Associates, industrial management consultants. Since 2004, Mr. Browne is chairman of OSI Pharmaceuticals Foundation which supports cancer and diabetes patient care and science education. He was a founding Director of the New York Biotechnology Association. He was graduated from Yale University (B.A.).
Mr. Fletcher was appointed Lead Independent Director on November 2, 2006. Since 1984, Mr. Fletcher has served as President of Fletcher & Company, Inc., a management consulting firm. Until the end of 1997, he was Chairman of Binnings Building Products Company, Inc. His previous business appointments include: adviser to Gabelli/Rosenthal LP, a leveraged buyout fund; Chairman of Keller Industries, building and consumer products; Senior Vice President of Booz-Allen & Hamilton; President of Booz-Allen Acquisition Services; Executive Vice President of Paine Webber Jackson & Curtis and a Director of Paine Webber, Inc.; and President of Baker, Weeks and Co., Inc., a New York Stock Exchange member firm. He is currently a Trustee of the Gabelli Growth Fund and a Director of the Gabelli Convertible and Income Securities Fund, Inc. He was graduated from Harvard College (A.B.) and Harvard Business School (M.B.A.).
Ms. Pressman has served as a consultant to Harris & Harris Group on nanotechnology, microsystems, intellectual property and in our due diligence work on certain prospective investments. She also acts as an observer for us at board meetings of certain portfolio companies in the Boston area. She is a business consultant providing advisory services to start-ups and venture capital companies. She consults internationally on technology transfer practices and metrics for non-profit and government organizations. From 1999 to 2001, she was Chair of the Survey Statistics and Metrics Committee of the Association of University Technology Managers. From 1989 until 2000, she was employed by the Massachusetts Institute of Technology in the Technology Licensing Office, serving as Technology Licensing Officer from 1989 to 1995 and Assistant Director from 1996 to 2000. She has previously been Senior Development Engineer at Lasertron, Inc., and a Member of the Solid State Materials Research Laboratory at Bell Laboratories. She was graduated from the Massachusetts Institute of Technology (S.B., Physics) and the Columbia School of Engineering (MSEE).
Since 1997, Mr. Ramsey has been a consultant in the area of human resources and venture capital. He is a retired founder and principal of Ramsey/Beirne Associates, Inc., an executive search firm that specialized in recruiting top officers for high-technology companies, many of which were backed by venture capital. He is a member of the board of directors and Chairman Emeritus of Bridges to Community, a non-governmental organization dedicated to construction projects in Nicaragua. As Chairman Emeritus, he serves on the Executive, Personnel and Administration and Fund Development Committees. He was graduated from Wittenberg University (B.A.).
Since October 2009, Mr. Roberts has been Managing Vice President Corporate Underwriting with Tower Group, Inc. From January 2006 to October 2009 he was President of AequiCap Insurance Company and from September 2007, President of AequiCap Program Administrators. He was also a senior officer of various other AequipCap affiliated entities. From 2002 to 2005, he was Executive Vice President and Chief Underwriting Officer of the Reinsurance Division of Alea North America Company and Senior Vice President of Alea North American Insurance Company. From 1999 to 2002, he was Chairman and Chief Executive Officer of The Insurance Company of New York, Dakota Specialty Insurance Company, and ReCor Insurance Company Inc., all members of Trenwick Group, Ltd. Mr. Roberts has held senior executive positions with other companies in the Trenwick Group. Mr. Roberts was graduated from Cornell University (A.B.).
From 2001 to 2006, Mr. Shanley was a Partner (now retired) of Deloitte & Touche LLP. From 1976 to 2001, he worked for Eisner LLP and was a partner from 1982 until 2001. During his over 30 years of public accounting experience, he served as lead audit partner on numerous audit engagements for public and private companies and companies making public stock offerings, including those requiring application of Sarbanes-Oxley Section 404. He served as lead audit partner primarily for biotech, pharmaceutical and high-tech companies, including companies enabled by nanotechnology. He has been actively involved on the Biotech Council of New Jersey, the New Jersey Technology Council, the New York Biotechnology Association, the Connecticut Venture Group, the Biotechnology Industry Organization and the NanoBusiness Alliance. He is a member of the board of directors of Redpoint Bio Corporation, a publicly held biotechnology company. He is an active member of the New York State Society of Certified Public Accountants and the American Institute of Certified Public Accountants. He is currently serving his fifth term on the New York State Society of CPA's Professional Ethics Committee and as of June 2009 is chairing that committee. He is a licensed Certified Public Accountant in New York. He was graduated from Fordham University (B.S.) and Long Island University (M.B.A. in Accounting).
= Chair of the Board
= Chair
= Member
= Independent Director
Chairman of the Board, Chief Executive Officer & Managing Director
= Chair of the Board
= Chair
= Member
= Independent Director
